No Excuse for Nonconformance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

No Excuse for Nonconformance
An updated book provides essential information for scientists who monitor microbial quality.


Pharmaceutical Technology
Volume 33, Issue 3

The US Pharmacopeia (USP) lists methodologies, standards, and requirements for microbiological tests used in assessing the quality of pharmaceutical and biotechnological products. These requirements are enforceable by the US Food and Drug Administration in compliance investigations. USP does not provide clear suggestions on how to perform these tests, however.


Microbial Limit and Bioburden Tests: Validation Approaches and Global Requirements, second edition, Lucia Clontz, CRC Press, Boca Raton, FL, 2008, 280 pp., ISBN: 13-978-1-4200-5348-7.
The first edition of Microbial Limit and Bioburden Tests provided a much-needed manual with practical instructions for carrying out the USP tests. Author Lucia Clontz described the compendial tests in a format familiar to practicing microbiologists.

The second edition of the book reflects the advances that have occured during the past several years, including the results of the efforts undertaken by USP, the European Pharmacopoeia, and the Japanese Pharmacopoeia to harmonize microbiological requirements and testing. The collaboration has provided industrial and regulatory microbiologists with uniform tests and reduced their workload.

Each of the chapters from the first edition has been brought up to date to conform to the new requirements, which include the modification of various testing procedures. For example, Salmonella is now tested using a different media than before. Also, the amount of sample needed for microbiological testing was changed from 10 g to 1 gm, with the exception of Salmonella testing. The harmonized text also includes a special exception for products that are only available in exceptionally small quantities and that are expensive, especially for biotechnological products.

New chapters have also been added to the book. The chapter titled "Biofilms" covers the pharmaceutical and biotechnological production equipment and materials susceptible to biofilm formation. The author provides practical advice for controlling and preventing the formation of biofilms by various means. One shortcoming, though, is the chapter's section on the qualification of chemical sanitization using biofilm cells, which would be more appropriate for a research environment than for a quality-control environment.

A chapter titled "Pharmaceutical Waters" provides a complete protocol for microbiological testing. The author deals in detail with sampling programs and sample collection and preservation. The section about recovery media is particularly well written. The chapter also discusses topics such as endotoxins testing of waters and the establishment of alert and action levels for microbiological bioburden and endotoxin levels.

Illustrations and simple diagrams are provided throughout the text to help microbiologists perform each test and procedure. In addition, separate sections provide advice about interpreting and validating each test. The procedures, interpretation of results, and validation guidelines follow the requirements in USP monographs, general chapters, and information chapters.

Several organizations market rapid methods for microbiological testing such as the identification of isolated microorganisms and the determination of microbial bioburden. Younger microbiologists often specialize in these rapid methods because they are automated and quicker than classical methods, which are labor-intensive and require days of incubation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here